Iatrogenic Creutzfeldt–Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients?

Boyd, Alison; Klug, Genevieve M J A; Masters, Colin L; Collins, Steven J

doi:10.5694/j.1326-5377.2011.tb03794.x

Topics

In reply: We thank Solvyns and Ralston for their thoughtful and heartfelt comments and their assistance in ensuring historical accuracy regarding the issues surrounding iatrogenic Creutzfeldt–Jakob disease (CJD) risk and recipients of the Australian Human Pituitary Hormone Program (AHPHP).

1 Australian National Creutzfeldt–Jakob Disease Registry, Department of Pathology, University of Melbourne, Melbourne, VIC.
2 Mental Health Research Institute, Melbourne, VIC.

Correspondence: aboyd@unimelb.edu.au

Competing interests:

The Australian National Creutzfeldt–Jakob Disease Registry is funded by the Australian Government Department of Health and Ageing. Steven Collins is the Medical Director of the CJD Support Group Network. He receives Fellowship and program grant funding from the National Health and Medical Research Council.

1. Boyd A, Klug GMJA, Schonberger LB, et al. Iatrogenic Creutzfeldt–Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients? Med J Aust 2010; 193: 366-369. <eMJA full text> <MJA full text>
2. Allars M. Report of the inquiry into the use of pituitary derived hormones in Australia and Creutzfeldt-Jakob disease. Canberra: AGPS, 1994: 630.

Online responses are no longer available. Please refer to our instructions for authors page for more information.